| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9312773 | Urology | 2005 | 6 Pages |
Abstract
Zoledronic acid administration for 1 year to patients with hormone-sensitive prostate cancer and bone metastases who were receiving androgen deprivation therapy was safe and prevented bone loss, as demonstrated by significant increases in bone mineral density and sustained suppression of biochemical markers of bone turnover.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Thomas J. Polascik, Robert W. Given, Charles Metzger, Sydney R. Julian, James C. Vestal, Gary S. Karlin, Craig S. Barkley, David L. Bilhartz, Laura T. McWhorter, Leo V. Lacerna,